SCHEMBL2980392

SCHEMBL2980392

Nc1ccc2[nH]c3c(c2c1)CN(c1ncc(C(=O)NO)cn1)CC3

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 10/20 0.54
HDAC1 Q13547 6/20 0.50
HDAC6 Q9UBN7 5/20 0.50
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
HDAC8 Q9BY41 2/20 0.44
HDAC2 Q92769 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2978478 0.90 HDAC1 (0.45) BAZ2BHDAC1HDAC6POLBGAA
SCHEMBL2979006 0.89 BAZ2B (0.55) BAZ2BHDAC1HDAC6POLBGAA
SCHEMBL2963961 0.88 BAZ2B (0.54) BAZ2BHDAC1HDAC6POLBGAA
SCHEMBL2978179 0.88 HDAC1 (0.65) BAZ2BHDAC1HDAC6KDM4EALDH1A1
SCHEMBL2965905 0.88 HDAC1 (0.65) BAZ2BHDAC1HDAC6POLBGAA
SCHEMBL2970696 0.87 BAZ2B (0.56) BAZ2BPOLBGAAKDM4EALDH1A1
SCHEMBL2981233 0.86 HDAC6 (0.51) BAZ2BHDAC1HDAC6POLBGAA
SCHEMBL2978845 0.85 HDAC1 (0.52) BAZ2BHDAC1HDAC6POLBGAA
SCHEMBL2970427 0.85 HDAC1 (0.48) HDAC1HDAC6POLBGAAHDAC8
SCHEMBL2980640 0.85 HDAC1 (0.52) BAZ2BHDAC1HDAC6POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772245-B2 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS, INC. (US) 2010-08-10 US claimed
US-20060199829-A1 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS, INC. 2006-09-07 US claimed
US-7772245-B2 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS, INC. (US) 2010-08-10 US disclosed
US-7772245-B2 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS, INC. (US) 2010-08-10 US disclosed
US-20060199829-A1 Inhibitors of histone deacetylase MIIKANA THERAPEUTICS, INC. 2006-09-07 US disclosed
WO-2006088949-A1 FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE MIIKANA THERAPEUTICS, INC. (US) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199829-A1 Inhibitors of histone deacetylase HDAC1, HDAC2, HDAC11 BAZ2B 33/4885HDAC1 1/4885HDAC6 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.